Fucosan can inhibit the tumour cell migration that is induced by the M2 macrophage conditioned medium, the function of CD4+ T lymphocytes, and especially the recruitment of Tregs by inhibiting CCL22 via the activity of NF-κB, which reduces CCL22 production. The gene discussed is NFKB1; the disease is neoplasm.